Risk of primary composite end point and secondary kidney and cardiovascular end points with canagliflozin (n=2099) compared with placebo (n=2099) with and without adjustment for postbaseline HbA1c (total n=4198)
| Outcome | Model | HR (95% CI) |
| Primary composite | Unadjusted | 0.67 (0.57 to 0.80) |
| Week 13 HbA1c | 0.71 (0.60 to 0.84) | |
| Time-varying HbA1c | 0.68 (0.57 to 0.80) | |
| Time-varying HbA1c spline | 0.68 (0.58 to 0.81) | |
| Kidney composite | Unadjusted | 0.66 (0.53 to 0.81) |
| Week 13 HbA1c | 0.68 (0.55 to 0.84) | |
| Time-varying HbA1c | 0.65 (0.53 to 0.81) | |
| Time-varying HbA1c spline | 0.66 (0.54 to 0.81) | |
| Cardiovascular death and heart failure hospitalization | Unadjusted | 0.66 (0.54 to 0.81) |
| Week 13 HbA1c | 0.70 (0.57 to 0.85) | |
| Time-varying HbA1c | 0.66 (0.54 to 0.81) | |
| Time-varying HbA1c spline | 0.67 (0.55 to 0.82) | |
| Doubling of creatinine | Unadjusted | 0.59 (0.46 to 0.74) |
| Week 13 HbA1c | 0.60 (0.48 to 0.76) | |
| Time-varying HbA1c | 0.58 (0.46 to 0.74) | |
| Time-varying HbA1c spline | 0.59 (0.46 to 0.74) | |
| ESKD | Unadjusted | 0.69 (0.54 to 0.88) |
| Unadjusted | 0.70 (0.55 to 0.90) | |
| Week 13 HbA1c | 0.68 (0.54 to 0.87) | |
| Time-varying HbA1c | 0.70 (0.55 to 0.89) | |
| Cardiovascular death | Unadjusted | 0.73 (0.56 to 0.95) |
| Week 13 HbA1c | 0.78 (0.60 to 1.01) | |
| Time-varying HbA1c | 0.74 (0.57 to 0.96) | |
| Time-varying HbA1c spline | 0.75 (0.58 to 0.97) | |
| Major adverse cardiovascular events | Unadjusted | 0.79 (0.65 to 0.95) |
| Week 13 HbA1c | 0.83 (0.69 to 1.01) | |
| Time-varying HbA1c | 0.81 (0.67 to 0.97) | |
| Time-varying HbA1c spline | 0.81 (0.67 to 0.97) |
ESKD, end-stage kidney disease; HbA1c, hemoglobin A1c.